Lack of correlation between the antibody to hepatitis B core antigen and survival after surgical resection for hepatitis C virus-related hepatocellular carcinoma

Nishikawa,Hiroki; Arimoto,Akira; Wakasa,Tomoko; Kita,Ryuichi; Kimura,Toru; Osaki,Yukio

doi:10.3892/or.2013.2422

Lack of correlation between the antibody to hepatitis B core antigen and survival after surgical resection for hepatitis C virus-related hepatocellular carcinoma

Authors:
- Hiroki Nishikawa
- Akira Arimoto
- Tomoko Wakasa
- Ryuichi Kita
- Toru Kimura
- Yukio Osaki
View Affiliations

Affiliations: Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Tennoji-ku, Osaka 543-0027, Japan, Department of Surgery, Osaka Red Cross Hospital, Tennoji-ku, Osaka 543-0027, Japan, Department of Pathology, Osaka Red Cross Hospital, Tennoji-ku, Osaka 543-0027, Japan
Published online on: April 24, 2013 https://doi.org/10.3892/or.2013.2422
Pages: 91-98

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The impact of antibodies to hepatitis B core antigen (anti-HBc) on survival after curative surgical resection (SR) for hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) remains unclear. The aim of the present study was to examine the relationship between anti-HBc positivity and survival of HCV-related HCC patients who underwent curative SR. A total of 222 patients with HCV-related, hepatitis B surface antigen (HBsAg)-negative HCC who underwent curative SR were analyzed. They included 119 anti-HBc-positive patients (53.6%) and 103 anti-HBc-negative patients (46.4%). Overall survival (OS) and recurrence-free survival (RFS) rates were compared between the two groups. The median follow-up periods in the anti-HBc-positive and anti-HBc-negative groups were 3.4 years (range, 0.3-10.9 years) and 3.2 years (range, 0.5-10.9 years), respectively. The 1-, 3- and 5-year cumulative OS rates were 88.8, 70.2 and 50.0%, respectively, in the anti-HBc-positive group and 95.8, 77.1 and 61.7% in the anti-HBc-negative group (P=0.300). The corresponding RFS rates were 68.7, 33.0 and 20.0%, respectively, in the anti-HBc-positive group and 74.4, 38.5 and 16.5% in the anti-HBc-negative group (P=0.482). Multivariate analyses identified serum albumin ≥3.8 g/dl (P=0.005) and the presence of microvascular invasion (P<0.001) as independent factors linked to OS, and interferon therapy after surgery (P=0.011), α-fetoprotein ≥40 ng/ml (P=0.030) and the presence of microvascular invasion (P<0.001) were significant predictors linked to RFS. In subgroup analyses according to maximum tumor size and background liver disease in terms of OS and RFS, no significant difference between the anti-HBc-positive and anti-HBc-negative groups was observed except in patients with non-cirrhotic liver in terms of RFS. In conclusion, anti-HBc-positivity is not a useful predictor for survival of patients with HCV-related HCC after curative SR.

View Figures

View References

1	Livraghi T, Mäkisalo H and Line PD: Treatment options in hepatocellular carcinoma today. Scand J Surg. 100:22–29. 2011.PubMed/NCBI
2	El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 142:1264–1273. 2012. View Article : Google Scholar : PubMed/NCBI
3	de Lope CR, Tremosini S, Forner A, et al: Management of HCC. J Hepatol. 56(Suppl 1): S75–S87. 2012.
4	El-Serag HB: Hepatocellular carcinoma. N Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
5	Umemura T and Kiyosawa K: Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res. 37(Suppl 2): S95–S100. 2007. View Article : Google Scholar
6	Nishikawa H, Osaki Y, Kita R, et al: Transcatheter arterial infusion chemotherapy prior to radiofrequency thermal ablation for single hepatocellular carcinoma reduces the risk of intrahepatic distant recurrence. Int J Oncol. 41:903–909. 2012.
7	Zhou WP, Lai EC, Li AJ, et al: A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg. 249:195–202. 2009. View Article : Google Scholar
8	Ohki T, Tateishi R, Goto E, et al: Influence of anti-HBc seropositivity on the risk of hepatocellular carcinoma in HCV-infected patients after adjusting for confounding factors. J Viral Hepat. 17:91–97. 2010. View Article : Google Scholar : PubMed/NCBI
9	Squadrito G, Pollicino T, Cacciola I, et al: Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer. 106:1326–1330. 2006. View Article : Google Scholar
10	Ikeda K, Marusawa H, Osaki Y, et al: Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med. 146:649–656. 2007. View Article : Google Scholar : PubMed/NCBI
11	Lok AS, Everhart JE and Di Bisceglie AM; HALT-C Trial Group. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology. 54:434–442. 2011. View Article : Google Scholar : PubMed/NCBI
12	Marusawa H, Osaki Y, Kimura T, et al: High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan. Gut. 45:284–288. 1999. View Article : Google Scholar : PubMed/NCBI
13	Shiota G, Oyama K, Udagawa A, et al: Occult hepatitis B virus infection in HBs antigen-negative hepatocellular carcinoma in a Japanese population: involvement of HBx and p53. J Med Virol. 62:151–158. 2000. View Article : Google Scholar
14	Jilg W, Sieger E, Zachoval R and Schätzl H: Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: high percentage of carriers of hepatitis B and C virus. J Hepatol. 23:14–20. 1995. View Article : Google Scholar : PubMed/NCBI
15	Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME and Raimondo G: Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 341:22–26. 1999. View Article : Google Scholar : PubMed/NCBI
16	Tanaka K, Nagao Y, Ide T, Kumashiro R and Sata M: Antibody to hepatitis B core antigen is associated with the development of hepatocellular carcinoma in hepatitis C virus-infected persons: a 12-year prospective study. Int J Mol Med. 17:827–832. 2006.
17	Bruix J and Sherman M: Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology. 42:1208–1236. 2005. View Article : Google Scholar
18	Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. Jpn J Surg. 19:98–129. 1989. View Article : Google Scholar : PubMed/NCBI
19	Marusawa H, Uemoto S, Hijikata M, et al: Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology. 31:488–495. 2000. View Article : Google Scholar : PubMed/NCBI
20	National Institutes of Health. Consensus Development Conference Statement. Management of hepatitis C: June 10–12, 2002. Hepatology. 36(Suppl 1): S3–S20. 2002.
21	Strader DB, Wright T, Thomas DL and Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 39:1147–1171. 2004. View Article : Google Scholar : PubMed/NCBI
22	Mazzaferro V, Romito R and Schiavo M; HCC Italian Task Force. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 44:1543–1554. 2006. View Article : Google Scholar : PubMed/NCBI
23	Lim KC, Chow PK, Allen JC, et al: Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg. 254:108–113. 2011. View Article : Google Scholar
24	Sakae M, Kubo S, Takemura S, et al: Effect of interferon therapy on first and second recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Hepatol Res. 42:564–573. 2012. View Article : Google Scholar
25	Tanimoto Y, Tashiro H, Aikata H, et al: Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection. Ann Surg Oncol. 19:418–425. 2012. View Article : Google Scholar
26	Singal AK, Freeman DH Jr and Anand BS: Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther. 32:851–858. 2010. View Article : Google Scholar
27	Lautz HU, Selberg O, Körber J, Bürger M and Müller MJ: Protein-calorie malnutrition in liver cirrhosis. Clin Investig. 70:478–486. 1992. View Article : Google Scholar : PubMed/NCBI
28	Italian Multicentre Cooperative Project on Nutrition in Liver Cirrhosis. Nutritional status in cirrhosis. J Hepatology. 21:317–335. 1994. View Article : Google Scholar
29	Nishikawa H, Osaki Y, Inuzuka T, et al: Branched-chain amino acid treatment before transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol. 18:1379–1384. 2012. View Article : Google Scholar
30	Nishikawa H, Osaki Y, Iguchi E, et al: The effect of long-term supplementation with branched-chain amino acid granules in patients with hepatitis C virus-related hepatocellular carcinoma after radiofrequency thermal ablation. J Clin Gastroenterol. 47:359–366. 2012. View Article : Google Scholar